KomFi. Academy

hard · CFA Level I Corporate Issuers

Amberfen Pharma is evaluating a research project with an initial outlay of 100 million. The project has a 4-year life. Depreciation is straight-line to zero over 4 years. The project is expected to generate annual revenues of $80 million and cash expenses of $30 million. The cost of capital is 12% and the tax rate is 25%.

What is the annual incremental after-tax operating cash flow for this project?

  1. 50.00 million
  2. 43.75 million
  3. 37.50 million

Sign up free to see the explanation and track your rank →

More CFA Level I Corporate Issuers practice

All Corporate Issuers questions · CFA Level I study guide · CFA Level I glossary · CFA Level I flashcards